摘要 Prostate cancer (PCa) is the second most common cancer among men worldwide and even ranks first in Europe. Although Asia is known as the region with the lowest PCa incidence, it has been rising rapidly over the last 20 years mostly due to the introduction of prostate-specific antigen (PSA) testing. Randomized PCa screening studies in Europe show a mortality reduction in favor of PSA-based screening but coincide with high proportions of unnecessary biopsies, overdiagnosis and subsequent overtreatment. Conclusive data on the value of PSA-based screening and hence the balance between harms and benefits in Asia is still lacking. Because of known racial variations, Asian countries should not directly apply the European screening models. Like in the western world also in Asia, new predictive markers, tools and risk stratification strategies hold great potential to improve the early detection of PCa and to reduce the worldwide existing negative aspects of PSA-based PCa screening.
Abstract: Prostate cancer (PCa) is the second most common cancer among men worldwide and even ranks first in Europe. Although Asia is known as the region with the lowest PCa incidence, it has been rising rapidly over the last 20 years mostly due to the introduction of prostate-specific antigen (PSA) testing. Randomized PCa screening studies in Europe show a mortality reduction in favor of PSA-based screening but coincide with high proportions of unnecessary biopsies, overdiagnosis and subsequent overtreatment. Conclusive data on the value of PSA-based screening and hence the balance between harms and benefits in Asia is still lacking. Because of known racial variations, Asian countries should not directly apply the European screening models. Like in the western world also in Asia, new predictive markers, tools and risk stratification strategies hold great potential to improve the early detection of PCa and to reduce the worldwide existing negative aspects of PSA-based PCa screening.
Kai Zhang, Chris H. Bangma, Monique J. Roobol. Prostate cancer screening in Europe and Asia[J]. Asian Journal of Urology, 2017, 4(2): 86-95.
Kai Zhang, Chris H. Bangma, Monique J. Roobol. Prostate cancer screening in Europe and Asia. Asian Journal of Urology, 2017, 4(2): 86-95.
[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin 2012; 2015(65):87-108. [2] Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet 2016;387:70-82. [3] Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92. [4] Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol 2016;70:862-74. [5] Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents, volumes I to IX: IARC CancerBase No. 9. Lyon, France: International Agency for Research on Cancer. World Health Organization Web site. http://ci5.iarc.fr. [6] Watanabe M, Nakayama T, Shiraishi T, Stemmermann GN, Yatani R. Comparative studies of prostate cancer in Japan versus the United States. A review. Urol Oncol 2000;5:274-83. [7] Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36. [8] Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35. [9] Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-32. [10] Shoag JE, Mittal S, Hu JC. Reevaluating PSA testing rates in the PLCO trial. N Engl J Med 2016;374:1795-6. [11] Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32. [12] Kobayashi M, Takezawa Y, Takechi H, Ito K, Yamamoto T, Suzuki K, et al. MP-11.12: Japanese prospective cohort study of screening for prostate cancer (JPSPC): the study concept and the first analyses on compliance and contamination for the PSA test (gunma section). Urology 2007;70(Supplement):97. [13] Ito K, Kakehi Y, Naito S, Okuyama A, Japanese Urological Association. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol 2008; 15:763-8. [14] Kitagawa Y, Namiki M. Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian J Androl 2015;17:475-80. [15] Kitagawa Y, Mizokami A, Nakashima K, Koshida K, Shimamura M, Miyazaki K, et al. Clinical outcomes of prostate cancer patients detected by prostate-specific antigen-based population screening in Kanazawa City, Japan. Int J Urol 2011;18:592-6. [16] Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of followup. N Engl J Med 2012;366:981-90. [17] Mok Y, Kimm H, Shin SY, Jee SH, Platz EA. Screening prostatespecific antigen concentration and prostate cancer mortality: the Korean heart study. Urology 2015;85:1111-6. [18] Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010;341:c4521. [19] Rabah DM, Arafa MA. Prostate cancer screening in a Saudi population: an explanatory trial study. Prostate Cancer Prostatic Dis 2010;13:191-4. [20] Tyson 2nd MD, Castle EP. Racial disparities in survival for patients with clinically localized prostate cancer adjusted for treatment effects. Mayo Clin Proc 2014;89:300-7. [21] Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006;97:1190-3. [22] Faisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, et al. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Urology 2014;84: 1434-41. [23] Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010. BMC Med 2015;13:171. [24] Bokhorst LP, Roobol MJ. Ethnicity and prostate cancer: the way to solve the screening problem? BMC Med 2015;13:179. [25] Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Bjork T, Gerdtsson A, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013;346:f2023. [26] Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37. [27] Vickers AJ, Eastham JA, Scardino PT, Lilja H. The memorial sloan kettering cancer center recommendations for prostate cancer screening. Urology 2016;91:12-8. [28] Catalona WJ. Baseline PSA testing for men in their 40s: currently available evidence strongly supports baseline PSA measurements in this age group. Oncol Willist Park 2014;28: 154-6. [29] Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65:1046-55. [30] Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8. [31] Bokhorst LP, Venderbos LD, Schroder FH, Bangma CH, Steyerberg EW, Roobol MJ. Do treatment differences between arms affect the main outcome of ERSPC Rotterdam? J Urol 2015;194:336-42. [32] Song C, Ahn H, Lee MS, Park J, Kwon TG, Kim HJ, et al. Mass screening for prostate cancer in Korea: a population based study. J Urol 2008;180:1949-53. [33] Kuwahara M, Tochigi T, Kawamura S, Ogata Y, Xu N, Wang H, et al. Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China. Urology 2003;61:137-41. [34] Moyer VA, Force USPST. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012;157:120-34. [35] Abdollah F, Dalela D, Sood A, Meyer CP, Hansen M, Han P, et al. The impact of 2011 United States preventive services task force panel update on PSA screening practice: a nationwide, and state-by-state level analyses. In: American Urological Association Annual Meeting San Diego 2016; 2016. [36] Aslani A, Minnillo BJ, Johnson B, Cherullo EE, Ponsky LE, Abouassaly R. The impact of recent screening recommendations on prostate cancer screening in a large health care system. J Urol 2014;191:1737-42. [37] Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US preventive-services task force recommendation discouraging prostate-specific antigenbased screening. J Clin Oncol 2015;33:2416-23. [38] Frendl D, Epstein M, Fouyazi H, Krajenta R, Rybicki B, Sokoloff M. Impact of guidelines on prostate cancer screening in a population-based setting. In: 2000-2014: preliminary results from the first AUA data Grant American Urological Association Annual Meeting San Diego 2016; 2016. [39] Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314: 2054-61. [40] Li J, Berkowitz Z, Hall IJ. Decrease in prostate cancer testing following the US preventive services task force (USPSTF) recommendations. J Am Board Fam Med 2015;28:491-3. [41] Miller C, Kabarriti A, Pulido J, Ziemba J, Guzzo T, Wein A, et al. United States preventive services task force prostate cancer screening guidelines were associated with age and race dependent changes in primary care prostate specific antigen based screening at a tertiary care center. In: American Urological Association Annual Meeting San Diego 2016; 2016. [42] Rezaee ME, Ward CE, Odom BD, Pollock M. Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012. Prev Med 2016; 82:73-6. [43] Sammon JD, Abdollah F, Choueiri TK, Kantoff PW, Nguyen PL, Menon M, et al. Prostate-specific antigen screening after 2012 US preventive Services Task Force recommendations. JAMA 2015;314:2077-9. [44] Sammon JD, Dalela D, Abdollah F, Sood A, Han P, Hansen M, et al. Age dependent variation in the effect of physician recommendations to undergo prostate specific antigen (PSA) screening following the United States preventive services task force 2012 statement against PSA screening. In: American Urological Association Annual Meeting San Diego 2016; 2016. [45] Shoag J, Halpern JA, Lee DJ, Mittal S, Ballman KV, Barbieri CE, et al. Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. J Urol 2016;196(4):1047-52. [46] Turini GI, Gjelsvik A, Golijanin D, Pareek G, Renzulli JI. The role of patient race and ethnicity in predicting physician recommendation of prostate-specific antigen (PSA) testing. In: American Urological Association Annual Meeting San Diego 2016; 2016. [47] Zavaski M, Meyer CP, Hanske J, Friedlander D, Cheng P, Menon M, et al. Differences in prostate specific antigen testing among urologists and primary care providers in the United States following the 2011 USPSTF recommendations. In: American Urological Association Annual Meeting San Diego 2016; 2016. [48] Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 2011;103:520-3. [49] Cohn JA, Wang CE, Lakeman JC, Silverstein JC, Brendler CB, Novakovic KR, et al. Primary care physician PSA screening practices before and after the final U.S. preventive services task force recommendation. Urol Oncol 2014;32:e23-30. [50] Zargar H, van den Bergh R, Moon D, Lawrentschuk N, Costello A, Murphy D. The impact of United States preventive Services Task Force (USPTSTF) recommendations against PSA testing on PSA testing in Australia. BJU Int 2016;119:110-5. [51] Fleshner KCS, Carlsson SV, Roobol MJ. A review of prostatespecific antigen screening and prostate cancer incidence patterns after the 2011-2012 United States preventive services task force recommendation. Nat Rev Urol 2016. in press. [52] Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50:710-4. [53] Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000;60: 756-9. [54] Sartori DA, Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol 2014;26:259-64. [55] Lughezzani G, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, et al. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol 2014;66: 906-12. [56] Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, et al. Serum isoform[-2] proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/mL: a multicentric European study. Eur Urol 2013;63:986-94. [57] Ng CF, Chiu PK, Lam NY, Lam HC, Lee KW, Hou SS. The prostate health index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol 2014;46:711-7. [58] Na R, Ye D, Liu F, Chen H, Qi J, Wu Y, et al. Performance of serum prostate-specific antigen isoform[-2] proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospitalbased biopsy population. Prostate 2014;74:1569-75. [59] Leapman MS, Carroll PR. New genetic markers for prostate Cancer. Urol Clin North Am 2016;43:7-15. [60] Sanguedolce F, Cormio A, Brunelli M, D'Amuri A, Carrieri G, Bufo P, et al. Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review. Clin Genitourin Cancer 2016;14:117-21. [61] Nicholson A, Mahon J, Boland A, Beale S, Dwan K, Fleeman N, et al. The clinical effectiveness and cost-effectiveness of the PROGENSA(R) prostate cancer antigen 3 assay and the prostate health index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2015;19(i-xxxi):1-191. [62] Okihara K, Ochiai A, Kamoi K, Fujizuka Y, Miki T, Ito K. Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countries. Int J Urol 2015;22:334-41. [63] Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9. [64] Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Prostate cancer gene 3(PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-67. [65] Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S, et al. Clinical utility of the prostate cancer gene 3(PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int 2013;111:928-33. [66] Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534-42. [67] Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 2016;70: 45-53. [68] Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging e reporting and data system: 2015, version 2. Eur Urol 2016;69:16-40. [69] Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746-57. [70] Turkbey B, Choyke PL. PIRADS 2.0: what is new? Diagn Interv Radiol 2015;21:382-4. [71] Pinto PA, Chung PH, Rastinehad AR, Baccala Jr AA, Kruecker J, Benjamin CJ, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186:1281-5. [72] Bjurlin MA, Mendhiratta N, Wysock JS, Taneja SS. Multiparametric MRI and targeted prostate biopsy: improvements in cancer detection, localization, and risk assessment. Cent Eur J Urol 2016;69:9-18. [73] Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasoundguided biopsy: a systematic review and meta-analysis. Eur Urol 2015;68:438-50. [74] Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combination of PI-RADS score and PSA density predicts biopsy outcome in biopsy naive patients. BJU Int 2016;119: 225-33. [75] Lee DH, Nam JK, Park SW, Lee SS, Han JY, Lee SD, et al. Visually estimated MRI targeted prostate biopsy could improve the detection of significant prostate cancer in patients with a PSA level <10 ng/mL. Yonsei Med J 2016;57:565-71. [76] Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ. Risk-based prostate cancer screening. Eur Urol 2012;61:652-61. [77] Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LF, Lein M, et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002;48:1279-87. [78] Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A, et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 2004;111:310-5. [79] Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005;173:1930-4. [80] Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the prostate Cancer prevention trial. J Natl Cancer Inst 2006; 98:529-34. [81] Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85. [82] Jeong CW, Lee S, Jung JW, Lee BK, Jeong SJ, Hong SK, et al. Mobile application-based Seoul national university prostate cancer risk calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men. PLoS One 2014;9:e94441. [83] Ku JH, Ahn JO, Lee CH, Lee NK, Park YH, Byun SS, et al. Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity. Urology 2002;60:475-9. [84] Gao HW, Li YL, Wu S, Wang YS, Zhang HF, Pan YZ, et al. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl 2005;7: 159-63. [85] Belbase NP, Agrawal CS, Pokharel PK, Agrawal S, Lamsal M, Shakya VC. Prostate cancer screening in a healthy population cohort in eastern Nepal: an explanatory trial study. Asian Pac J Cancer Prev 2013;14:2835-8. [86] Vu Le C, Dao OQ, Khac Tran LN. Mass screening of prostate cancer in Vietnam: current status and our opinions. Urol Oncol 2010;28:673-6.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
